To investigate the potential prognostic value of necroptosis-associated lncRNAs (NALncRNAs)in patients with ovarian cancer.
Gene expression data from ovarian cancer patients with clinical data were downloaded from TCGA database. This is the base data for screening NALncRNAs that represent different survival times.lncRNA risk models were constructed by Cox regression analysis and evaluated for their prognostic value. The link between lncRNA signatures and related pathways, immune cell activity, immunological checkpoints, m6A-related genes, and gene mutations was also investigated.
In this study, eight NALncRNAs including USP30-AS1, MINCR, LINC01096, DNM3OS, LINC02574, DTNB-AS1, ACAP2-IT1, and ILVBL-AS1, all of which were well represented for the outcome of ovarian cancer patients. Noemogram after calibration curve validation has good clinical utility. Risk signatures were shown to be abundant in various pathways related to immunology and cell proliferation, according to gene set enrichment analysis. Patients' late survival outcome corresponds to differences in immune cells, immune checkpoints, immune function, etc.A better immune microenvironment would facilitate late survival, but inexplicably patients with long survival times have a higher immune escape. Patients with high mutations in genes appear to have better survival outcomes.
This study identified eight NALncRNAs markers for the first time, providing a valuable basis for more accurate prediction of ovarian cancer prognosis.